Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$28.61 USD
+0.70 (2.51%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $28.60 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 1 - 20 ( 721 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Solid Start to Year; New Share Buyback; Expect Near Term Exparel Duration Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Expect Meaningful Multiple Expansion in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4/FY23: Laying the Foundation for EXPAREL Growth Ahead of NOPAIN
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Driving Further EXPAREL Volume Expansion Through GPO Agreement
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Pacira a 2024 Top Pick; Room For Big 2024 Sentiment Shift on Historically Cheap Stock
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O